Ghent University Academic Bibliography

Advanced

High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: Results of a survey in EORTC institutes

Christian Giro, Berhnard Berger, Bölke Edwin, Frank Ciernik, FREDERIC DUPREZ UGent, Laura Locati, Sophie Maillard, Mahmut Ozsahin, Raphael Pfeffer and Gerry Robertson, et al. (2009) RADIOTHERAPY AND ONCOLOGY. 90(2). p.166-171
abstract
OBJECTIVE: Examination of the rate of grade III or grade IV radiation dermatitis during treatment of head and neck cancer (HNC) with radiotherapy (RT) and concurrent cetuximab in EORTC centres. MATERIALS AND METHOD: A questionnaire was sent to all members of the EORTC Radiation Oncology Group and Head and Neck Group (111 institutions) to evaluate the widespread use of cetuximab and radiotherapy in HNC and to estimate the frequency of grades III and IV skin reactions in the radiation portals associated with this protocol. Co-morbidities, RT schedules and co-medications were also recorded. RESULTS: We received responses from 28 institutions in 11 countries. A total of 125 HNC patients from 15 institutions were treated with cetuximab and concurrent RT. Information about the skin reactions was available from 71 patients. Of these 36 had no grade III/IV adverse effects in the RT field, 15 had a grade III and 20 had grade IV radiation dermatitis. No detectable relation of grades III and IV radiation dermatitis with co-morbidities such as liver insufficiency or renal dysfunction was found. CONCLUSION: According to the results of the questionnaire, grade III/IV radiation dermatitis is observed in 49% of HNC patients treated with cetuximab and concurrent RT. A systematic clinical monitoring of cutaneous side effects during RT plus cetuximab is advised to ensure the safety of this protocol.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
journal title
RADIOTHERAPY AND ONCOLOGY
Radiother. Oncol.
volume
90
issue
2
pages
166 - 171
Web of Science type
Article
Web of Science id
000264039100002
JCR category
RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
JCR impact factor
4.343 (2009)
JCR rank
8/104 (2009)
JCR quartile
1 (2009)
ISSN
0167-8140
DOI
10.1016/j.radonc.2008.09.007
language
English
UGent publication?
yes
classification
A1
copyright statement
I don't know the status of the copyright for this publication
id
663377
handle
http://hdl.handle.net/1854/LU-663377
date created
2009-05-22 08:49:18
date last changed
2010-01-22 12:32:38
@article{663377,
  abstract     = {OBJECTIVE: Examination of the rate of grade III or grade IV radiation dermatitis during treatment of head and neck cancer (HNC) with radiotherapy (RT) and concurrent cetuximab in EORTC centres. MATERIALS AND METHOD: A questionnaire was sent to all members of the EORTC Radiation Oncology Group and Head and Neck Group (111 institutions) to evaluate the widespread use of cetuximab and radiotherapy in HNC and to estimate the frequency of grades III and IV skin reactions in the radiation portals associated with this protocol. Co-morbidities, RT schedules and co-medications were also recorded. RESULTS: We received responses from 28 institutions in 11 countries. A total of 125 HNC patients from 15 institutions were treated with cetuximab and concurrent RT. Information about the skin reactions was available from 71 patients. Of these 36 had no grade III/IV adverse effects in the RT field, 15 had a grade III and 20 had grade IV radiation dermatitis. No detectable relation of grades III and IV radiation dermatitis with co-morbidities such as liver insufficiency or renal dysfunction was found. CONCLUSION: According to the results of the questionnaire, grade III/IV radiation dermatitis is observed in 49\% of HNC patients treated with cetuximab and concurrent RT. A systematic clinical monitoring of cutaneous side effects during RT plus cetuximab is advised to ensure the safety of this protocol.},
  author       = {Giro, Christian and Berger, Berhnard and Edwin, B{\"o}lke and Ciernik, Frank and DUPREZ, FREDERIC and Locati, Laura and Maillard, Sophie and Ozsahin, Mahmut and Pfeffer, Raphael and Robertson, Gerry and Langendijk, Johannes and Budach, Wilfried},
  issn         = {0167-8140},
  journal      = {RADIOTHERAPY AND ONCOLOGY},
  language     = {eng},
  number       = {2},
  pages        = {166--171},
  title        = {High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: Results of a survey in EORTC institutes},
  url          = {http://dx.doi.org/10.1016/j.radonc.2008.09.007},
  volume       = {90},
  year         = {2009},
}

Chicago
Giro, Christian, Berhnard Berger, Bölke Edwin, Frank Ciernik, Fréderic Duprez, Laura Locati, Sophie Maillard, et al. 2009. “High Rate of Severe Radiation Dermatitis During Radiation Therapy with Concurrent Cetuximab in Head and Neck Cancer: Results of a Survey in EORTC Institutes.” Radiotherapy and Oncology 90 (2): 166–171.
APA
Giro, C., Berger, B., Edwin, B., Ciernik, F., Duprez, F., Locati, L., Maillard, S., et al. (2009). High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: Results of a survey in EORTC institutes. RADIOTHERAPY AND ONCOLOGY, 90(2), 166–171.
Vancouver
1.
Giro C, Berger B, Edwin B, Ciernik F, Duprez F, Locati L, et al. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: Results of a survey in EORTC institutes. RADIOTHERAPY AND ONCOLOGY. 2009;90(2):166–71.
MLA
Giro, Christian, Berhnard Berger, Bölke Edwin, et al. “High Rate of Severe Radiation Dermatitis During Radiation Therapy with Concurrent Cetuximab in Head and Neck Cancer: Results of a Survey in EORTC Institutes.” RADIOTHERAPY AND ONCOLOGY 90.2 (2009): 166–171. Print.